BioSpace News Archive

Waters Corporation (NYSE:WAT) Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Cowen Healthcare Conference on Wednesday, March 9th, 2022 at 2:10PM Eastern Standard Time.

TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA approved inducement grants of stock options to purchase an aggregate of 63,800 shares of its common stock to 17 newly-hired employees, with a grant date of February 23, 2022.

Aquestive Therapeutics, Inc. today announced positive topline results from Part 1 of the EPIPHAST study for its AQST-109 epinephrine oral film.

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval of Kapruvia® (difelikefalin).

Ocugen, Inc. reported fourth quarter and full year 2021 financial results along with a general business update.

Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that new preclinical data will be presented in a poster at the 2022 American Academy of Allergy Asthma and Immunology (AAAAI) annual meeting.

SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the Cowen 42nd Annual Health Care Conference.

Amarin Corporation plc (NASDAQ: AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, is scheduled to participate virtually in a fireside chat at the Cowen 42nd Annual Health Care Conference on Monday, March 7 from 9:10 AM – 9:40 AM ET.

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will hold a conference call and live webcast on Wednesday, March 2, 2022 at 4:30 p.m. Eastern Time (ET) to review its 2021 financial results and provide a business update.

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the completion of last patient last visit in its Phase Ib combination trial for mTNBC (metastatic Triple-Negative Breast Cancer) patients in Australia.